MYO9A

Across TCGA pan-cancer cohorts, MYO9A Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated MYO9A data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYO9A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYO9A expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, KICH, and SARC are the cancer types where MYO9A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.963	0.603	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	OS	Median	All	0.109	0.839	<.001	12	view →
BLCA	DFS	Median	II,III,IV	0.631	0.321	.024	10	view →
SCLC	DFS	Median	All	0.289	0.638	.012	9	view →
PAAD	DFS	Median	All	0.112	0.504	.025	6	view →
LUSC	DFS	Median	All	0.241	0.711	.038	6	view →
LIHC	DFS	Median	All	0.246	0.560	.013	6	view →
SKCM	DFS	Median	IV	0.134	0.589	.031	3	view →
CESC	OS	Median	All	0.736	0.879	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MYO9A–UCEC (DFS)

Open the UCEC breakdown →